Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of CKD-333 in Healthy Volunteers
NCT04019743Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jul 2019
- Primary completion
- Aug 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of candesartan cilexetil, amlodipine and atorvastatin in hypertension (HTN) and dyslipidemia (6 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area Under the Concentration-time Curve from time zero to last quantifiable concentration and Maximum Plasma Concentration. Started Jul 2019; status: completed.
02
Drugs
candesartan cilexetilamlodipineatorvastatin
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04019743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019743.